CDC clears Novavax monovalent COVID-19 boosters for adults 18 and older | CDC Online Newsroom
Today, CDC Director Rochelle P. Walensky, MD, MPH, signed a decision memorandum authorizing Novavax Adult Monovalent COVID-19 Boosters.
This action gives people aged 18 and over the option of receiving a monovalent Novavax booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna booster if they have completed the primary vaccination but have not yet received a COVID-19 booster – and if they can’t or won’t get mRNA vaccines.
Some may not be able to receive an mRNA vaccine due to an allergy to a component of a COVID-19 mRNA vaccine, or as a result of a history of severe allergic reaction (such as anaphylaxis) after a previous dose of a COVID-19 mRNA vaccine, or lack of availability of an mRNA vaccine. People aged 18 and over can also choose to receive a monovalent Novavax booster if they do not wish to receive mRNA vaccines and would not otherwise receive a booster dose.
The FDA’s authorization of monovalent COVID-19 boosters and the CDC’s recommendation for use are significant advances in our nation’s comprehensive immunization program — a program that has helped provide increased protection for all Americans against COVID-19. illness and death from COVID-19.